Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care

Project description

Reawakening the immune system to fight cancer

Tumours often deploy a variety of immune evasion strategies to escape detection and destruction by the body’s immune system. These include expression of immune checkpoint molecules to inhibit T cell activity, the expression of immunosuppressive cytokines, as well as the recruitment of regulatory T cells to dampen immune responses. Therefore, reawakening the immune system is a promising cancer treatment strategy. The EIC-funded NTX1088 project brings to the clinic an innovative antibody targeting the human poliovirus receptor (PVR) which is a key regulator of immune activation and is overexpressed in various cancer cells. The anti-PVR antibody works to restore immune cell function by activating T cells and natural killer cells against cancer.

Objective

Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before. A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

NECTIN THERAPEUTICS LTD
Net EU contribution
€ 2 499 998,90
Address
HI-TECH CAMPUS GIVAT RAM
91390 JERUSALEM
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 571 427,00